Sydney, Mar 22, 2019 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) CEO Steven Lydeamore, recently appointed to the company, is interviewed by ABN Newswire on the development of Irritable Bowl Syndrome (IBS) dietary supplements to address the growing need for a product that addresses the full range of IBS symptoms.
To view the video interview, please visit:
http://www.abnnewswire.net/press/en/96630/anr
To view the Pitt Street Research Report - "Following the Gut" , please visit:
http://abnnewswire.net/lnk/33S39548
About Anatara Lifesciences Limited
Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing productsfor human and animal health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.
| ||
|
